Welcome to today s webinar

Similar documents
Arthur H. Rubenstein Auditorium at the Smilow Center for Translational Research. Penn Medicine 3400 Civic Center Blvd Philadelphia, PA 19104

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy

Dementia: It s Not Always Alzheimer s

YEARS & COUNTING Annual Report

First US Plan to Address Alzheimer s Disease

Designing patient-centered clinical trials: Results of the MDIC project to use patient preference information to design clinical trials

National Plan to Address Alzheimer s Disease: 2013 Update. now available at

Medications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center

Re: Request for Information: Updating the Alzheimer s Disease-Related Dementias Research Priorities

Clinical Trial Glossary

annual report

Evaluations. Alzheimer s Disease A Public Health Response. Viewer Call-In. July 19, Guest Speakers. Thanks to our Sponsors:

Community Benefit Strategic Implementation Plan. Better together.

WHO, WHAT, WHEN AND WHERE OF PARKINSON S DIAGNOSIS. MJFF Third Thursdays Webinar March 17, 2016

National Alzheimer s project U.S.

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Comprehensive Approach to DLB Management

MOVEMENT DISORDERS AND DEMENTIA

THE TEXAS CANCER PLAN KAREN TORGES CHAIR, CANCER ALLIANCE OF TEXAS

Update on the DLB Module. ADC Directors Meeting Baltimore, MD October 14-15, 2016

Dementia, Cognitive Aging Services and Support

Evaluations. Dementia Update: A New National Plan for Alzheimer s Disease Research, Care and Services. Disclosure Statements.

Dementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota

Primary Care Workshop Agenda

Corporate Presentation August 6, 2015

OCTOBER EOEA and the Alzheimer s Association have organized implementation of the plan around its five major recommendations:

Assessing and Managing the Patient with Cognitive Decline

Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University

Update on the DLB Module. ADC Directors Meeting Baltimore, MD October 14-15, 2016

Membership Information and Application

Collaborating to Develop Digital Biomarkers with Passive Data Collection

2017 Phoenix Clinical Research Fair Program of Events

Thank you for joining today, please wait while others sign in.

Alzheimer s disease. The future of clinical trials: big problem, Big Data, big solution?

Support for Family Caregivers in the Context of Dementia: Promising Programs & Implications for State Medicaid Policy

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE SCOPE. Dementia: the management of dementia, including the use of antipsychotic medication in older people

Approved Care Model for Project 3gi: Integration of Palliative Care into the PCMH Model

Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry

Thank you for your ongoing support and interest in the investigational medicine RG6042 for Huntington s disease (HD).

CSF Aβ1-42 predicts cognitive impairment in de novo PD patients

MHCC Research Demonstration Projects on Mental Health and Homelessness: Toronto Proposal

Clinical Trials: Improving the Care of People Living With Cancer

Building Quality Into Outpatient Dementia Care For Mainers

ALZHEIMER S DISEASE FROM RESEARCH TO CARE: A COLLABORATIVE SEARCH FOR NEW DISCOVERIES

What is an HDSA Center of Excellence?

The Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing an example of Australian research on Alzheimer s disease

Clinical Trials: Questions and Answers

Redesigning Wisconsin s Dementia Care System

Mental Health Workshop Planning Kit

3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion

Appendix N: Research recommendations

UND GERIATRIC MEDICINE FELLOWSHIP CURRICULUM HOSPICE AND PALLIATIVE CARE

EXPLORING OPPORTUNITIES TO PARTNER TOWARD CURES FOR PD. Chicago Clinical Research Fair June 11, 2016

Form D1: Clinician Diagnosis

Call for Applications

Dementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.

BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018

The Academy Capitol Forum: Meet the Experts. Diagnosing Which Health Treatments Improve Outcomes: A PCORI Overview and How to Get Involved

Stroke Rehab Definitions Framework Self-Assessment Tool Acute Integrated Stroke Unit

Rural Outreach at the Knight ARDC

Update on functional brain imaging in Movement Disorders

PROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS

CREATION OF A TORONTO CENTRE FOR DEMENTIA RESEARCH

Health System Preparedness of Six EU Countries for a Future Alzheimer s Treatment. European Health Forum Gastein Soeren Mattke Oct 3, 2018

Suggested Topics for Milestones 2019 Speakers

Elliot Senior Specialty Services. in Greater Manchester. 138 Webster Street Manchester NH

Basic Standards for Residency/Fellowship Training in Geriatric Psychiatry

Pocket Reference to Alzheimer s Disease Management

Progress from the Patient-Centered Outcomes Research Institute (PCORI)

CFHI s Open Call for Innovations in Palliative and End-of-Life Care

SUBSTANCE USE DISORDERS

How to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.

INTRODUCTION TO THE REMOTE ASSESSMENT OF DISEASE AND RELAPSE (RADAR) PROGRAMME

Regulatory Challenges across Dementia Subtypes European View

Pediatric Primary Care Mental Health Specialist Certification Exam. Detailed Content Outline


A New Genetic Test for Alzheimer s Disease and Dementia Risk with transformational potential

THE MULLER INSTITUTE FOR SENIOR HEALTH

Integrating Medical and Social Support for Elderly System & Technology Enabled Service Innovations. Dr Christina MAW Hospital Authority, Hong Kong

Screening and Management of Behavioral and Psychiatric Symptoms Associated with Dementia

PD ExpertBriefing: Cognition and PD: What You ve Always Wanted to Know But Were Too Afraid to Ask. Presented By: Tuesday, March 22, 2011 at 1:00 PM ET

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

DEMENS MED LEWYLEGEMER OG PARKINSON DEMENS

Chronic Effects of Neurotrauma Consortium (CENC)

Vanderbilt & Qsource Webinar Series

The PD You Don t See: Cognitive and Non-motor Symptoms

Ontario s Dementia Strategy. 13th Annual Geriatric Emergency Management Nursing Network Conference October 17, 2017

WEEKLY ING April 17, 2018 Table of Contents

Coordinating Care Between Neurology and Psychiatry to Improve the Diagnosis and Treatment of Parkinson s Disease Psychosis

Chronic Disease/Caregiver Management - Open Grant Opportunities

Home Based Memory Rehabilitation Programme

The Need for an Inter-Professional Approach for Working with Older Persons

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

Geriatrics / Gerontology Education

How Fintech & Matched Savings Can Help Your Clients & Your Program: Introducing EARN s SaverLife Platform. November 15, 2017

10th Medicine Review Course st July Prakash Kumar

HVTN 505 Study HIV Vaccine Candidate Not Effective

Palliative and end of life care Priority Setting Partnership

Canadian Mental Health Association

Transcription:

Welcome to today s webinar We will begin the webinar at 2:00 p.m. Eastern All attendee lines are automatically muted. This webinar is being recorded and will be posted on LBDA s Youtube page. Throughout the event, please submit your questions using the Q&A option.

How to Utilize the LBDA Research Centers of Excellence (RCOE) Program Dave Irwin, MD University of Pennsylvania Co-Director, LBDA Research Center of Excellence

Webinar Outline Review goals, structure and progress of LBDA Research Centers of Excellence Program Discuss general aspects to participation in clinical research and clinical trials.

LBDA Research Centers of Excellence (RCOE) 25 Centers Across the US Established through an application and peer-review chosen by committee and announced in October of 2017. GOALS Increase access to high quality clinical care over the course of LBD. Increase knowledge of LBD among medical and allied (or other) professionals. Establish a clinical trials-ready network of LBD centers. Create infrastructure and resources to advance LBD research toward the overall goal of development of new symptomatic and disease-modifying therapeutics.

Goal: Increase access to high quality clinical care over the course of LBD. It is not uncommon for LBD diagnosis to take several years to establish with multiple visits across different specialists and subspecialists despite being a common cause of dementia. Delay in diagnosis results in increased caregiver/patient burden and morbidity. Galvin et al, Alzheimer Dis Assoc Disord. 2010

Goal: Increase access to high quality clinical care over the course of LBD. LBD IS A MULTI-SYSTEM DISEASE Coordinated care among health care professionals (e.g. PCP, neurologist, physical therapist). REM Sleep Behavior Disorder Orthostatic Hypotension Constipation Agitation Motor Parkinsonism Dementia Cognitive Fluctuations/Excessive Daytime Sleepiness Delusions Depression/Anxiety Visual Hallucinations

Goal: Increase knowledge of LBD among medical and allied (or other) professionals. More efficient referral of LBD patients to neurologist for more rapid diagnosis. Improve care for LBD patients in emergency settings and other settings where treatment is from nonspecialist. Improve symptom management of LBD by all treating health care providers.

Goal: Establish a clinical trials-ready network of LBD centers. Improve access for patients seeking therapeutic trials. Stimulate industry to invest in LBD therapeutic development by demonstrating feasibility of conducting trial. Improve quality of LBD therapeutic trials conducted by centers with experience in patient population.

Goal: Create infrastructure and resources to advance LBD research toward the overall goal of development of new symptomatic and diseasemodifying therapeutics. Researchers and institutions combing efforts to accelerate discovery. Engage with industry to stimulate interest in LBD trials and advise trial design for higher-likelihood for success. Allow data/biospecimens collected for therapeutic trials to be used by research community for further knowledge outside of trial goals.

Penn LBDA Research Center of Excellence PENN FTDC PENN PD&MDC PADRECC David Irwin, MD Andrew Siderowf, MD John Duda, MD Cognitive specialists, clinical nurses, genetic counselor, neuropsychologist, researchers, social workers and research coordinators. Movement Disorders specialists, clinical nurses, research assistants, social workers, counselling program and The Dan Aaron Center Parkinson Rehabilitation Center. Comprehensive multidisciplinary clinic with a neuropsychologist, a geriatric psychiatrist and a social worker to help care for Veterans with LBD.

LBDA RCOE Investigator Meeting First Annual Meeting on December 14 th 2017 with 4 work-groups: 1. Clinical Care and Professional Education 2. Community Education and Support 3. Clinical Trial Design & Optimization 4. Industry Engagement

LBDA RCOE Survey Clinical Patients DLB PDD Annual New 1361 1288 Annual Return ~3,000 ~4500

LBDA RCOE Survey Clinical Trials Experience 18/24 (~80%) sites active in > 5 clinical trials in last year 21/24 (88%) sites active in > 2 clinical trials in past year

Clinical Care and Professional Education WG Important clinical milestones in LBD management identified Referrals to allied health therapies and utilization of community resources. Increasing awareness and disseminating LBD knowledge to healthcare professionals remains a critical priority. Toolkit for PCPs and other health care professionals for LBD care. Encouraging LBD education events at RCOE sites.

Clinical Care and Professional Education Videos of presentations will be available at: www.lbda.org

Community Education and Support WG Improving access and quality for caregiver support groups at RCOE sites based on caregiver feedback. Most sites favored targeting caregivers and/or early-stage patients with LBD. Trained facilitators were described as essential. Sources of patient/family education for LBDA RCOE sites LBA-produced materials LBD booklet from the National Institutes of Health Materials produced by the individual sites.

Clinical Trial Design / Optimization WG Engage Caregivers (surveys, networks) Comprehensively address current care challenges Develop clinically meaningful LBD outcome measures Account for unique aspects of LBD Facilitate academic and industry partnerships for biomarker development / validation

Biomarkers: Overall Goals 1)Diagnostic Use 1)Early Diagnosis (MCI-DLB/prodromal DLB) 2)Differentiation from AD, FTLD, VASC 3)DLB subgroup stratification 2)Prognostic Use 1)Track disease progression 2)Target engagement (disease modifying therapies)

Industry Engagement WG Central resource for exploring collaborations between the RCOE and industry on LBD clinical trials. Determine requirements of data sharing and publication plans Optimization of protocols Centralized data resource on the clinical trial capabilities of all RCOE sites. Facilitate clinical research collaboration among RCOEs and expedite site selection for industry-sponsored trials. Guidance on establishing expert panels to advise clinical trial sponsors.

Webinar Outline Review goals, structure and progress of LBDA Research Centers of Excellence Program Discuss general aspects to participation in clinical research and clinical trials.

What is research? Research A study done to answer a question. Clinical Research- Studies in which people participate as patients or healthy volunteers. Scientists do research when they re not sure what will work best to help people with an illness. Other terms for clinical research are clinical trial, protocol, study, and experiment. From: fda.gov

Definitions: Types of Research Studies Observational Research (Diagnostic/ Natural History Studies) No intervention Collection of data (Cross-Sectional vs. Longitudinal) Cognitive testing Blood/CSF Imaging Genetics

Observational Research (Natural History Studies) Longitudinal study using DLB-specific clinical assessments, blood, CSF, MRI and DATSCAN across 9 centers in US. Goal is to facilitate clinical trials and advance science of LBD clinical care.

Observational Research (Natural History Studies) Recruiting ethnically diverse cohort of DLB patients for annual biofluid and clinical assessments. Performing RNA expression experiments from DLB brain tissue to develop new biomarkers.

Observational Research (Natural History Studies) Enroll and follow DLB patients and perform MRI, DATSCAN, PET amyloid, PET Tau imaging. Provide critical tissue validation of imaging studies.

Observational Research (Natural History Studies) Recruiting PDD and DLB for 3 year annual cognitive follow up and PET imaging of amyloid, tau and dopamine transport system to classify patients based on biomarker profiles.

Definitions: Types of Research Studies Therapeutic Trials Pharmacologic agents (medications) Non-pharmacologic agents Behavioral interventions Devices

Clinical Trial Strategies for DLB Potential disease modifying therapies Target biology of disease Symptomatic Treatments Target symptoms of disease Behavioral strategies/interventions Psychiatric medications Devices (e.g. non-invasive brain stimulation)

Clinical Trials Overview FDA Designation for Accelerated Drug Development National Alzheimer s disease Prevention Act (NAPA) Image from: http://neurosciences.ucsd.edu/

Important aspects of therapeutic trials for patients Most therapeutic trials are placebo-controlled and blinded Ensure we can objectively detect a positive effect Maximize the number of patients to receive active drug There is a screening visit to determine eligibility Criteria to help ensure participation is safe Patients may not benefit directly from some trials Important meaningful contribution which many patients/families value It is important to follow closely with your physician Safety monitoring and outcome measures www.clinicaltrials.gov/ct2/about-studies/learn

Questions to Consider ALL RESEARCH What is the purpose of the study? What tests and treatments (or procedures) will be involved? What are the risks? What are the potential benefits for participation? How long will the study last and how frequent are visits? Will I learn the results of my tests? What steps ensure my privacy? Will my expenses be reimbursed? Will I be paid? CLINICAL TRIALS Can I continue my current medications? What are the chances that I will receive a placebo? Is there an open-label period? When can we expect trial results? Adapted from: National Institute on Aging/National Institutes of Health, Participating in Alzheimer s Research and www.lbda.org

Where to find clinical trial information Your physician Clinical trials.gov (www.clinicaltrials.gov) LBDA (www.lbda.org) Parkinson s Disease biomarker Program (PDBP) (https://pdbp.ninds.nih.gov) Alzforum (www.alzforum.org) Alzheimer s Association Trial Match (https://trialmatch.alz.org/findclinical-trials) Michael J. Fox Foundation (https://foxtrialfinder.michaeljfox.org/findtrials)

LBDA Resources: WWW.LBDA.ORG EDUCATION- Disease pathogenesis, symptoms and treatment. SUPPORT- RCOE centers, support groups, caregiver information. RESEARCH- Clinical research/trials listing. EVENTS- Webinars, Talks, Fundraisers.

Interested in Learning More? Visit www.lbda.org/rcoe

CONTACT US www.lbda.org (404) 935-6444 lbda@lbda.org LBDA is a 501(c)3 organization